Article
Chemistry, Medicinal
Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Valeria I. Gerasimova, Alexander N. Kornetov, Anton J. M. Loonen, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: This study compared the changes in cytokine levels in schizophrenia patients receiving atypical antipsychotics with or without metabolic syndrome. The results showed that treatment with atypical antipsychotics had different effects on inflammatory cytokine levels depending on the presence of MetS. Patients with MetS experienced increased levels of certain cytokines, while those without MetS had decreased levels of other cytokines after treatment.
Review
Chemistry, Medicinal
Marco Carli, Shivakumar Kolachalam, Biancamaria Longoni, Anna Pintaudi, Marco Baldini, Stefano Aringhieri, Irene Fasciani, Paolo Annibale, Roberto Maggio, Marco Scarselli
Summary: Atypical antipsychotics can cause metabolic syndrome, including weight gain, dyslipidemia, type 2 diabetes, and high blood pressure. Olanzapine and clozapine have the highest risk of metabolic alterations, while newer medications like ziprasidone and lurasidone may be more tolerable in terms of metabolic profile. Differences in efficacy among antipsychotics should be considered, with clozapine being the most effective but potentially associated with increased metabolic risks. A multidisciplinary approach combining psychoeducation and therapeutic drug monitoring is proposed as a first-line strategy to avoid metabolic syndrome.
Review
Clinical Neurology
Xuemei Liao, Hui Ye, Tianmei Si
Summary: Metabolic syndrome occurs more frequently in patients with schizophrenia than in the general population, with antipsychotic medication being a primary risk factor. Different antipsychotics may have different impacts on glucose and lipid metabolism due to their pharmacological affinity to MetS-related receptors, and switching to lower metabolic risk antipsychotics may improve patients' metabolic parameters. This review aims to discuss strategies for switching antipsychotic medications and their impact on metabolic abnormalities in patients with schizophrenia.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Review
Endocrinology & Metabolism
Maria Fonseca, Francisca Carmo, Fatima Martel
Summary: Atypical antipsychotics (AAPs) have beneficial effects in treating mental diseases, but they also have undesired metabolic side effects. These side effects are related to the actions of AAPs in metabolic organs and the central and peripheral nervous system. A better understanding of the molecular targets and mechanisms linking AAPs with metabolic syndrome is necessary to develop AAPs with less adverse effects.
JOURNAL OF NEUROENDOCRINOLOGY
(2023)
Article
Health Care Sciences & Services
Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Anastasiia A. Goncharova, Arkadiy Semke, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: Metabolic syndrome (MetS) is a common complication of schizophrenia that is exacerbated by long-term use of antipsychotics. The study found that levels of leptin were significantly increased in MetS patients, while ghrelin levels were significantly decreased. There were fewer significant correlations between ghrelin and other hormones in MetS patients compared to those without MetS.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Psychiatry
Katherine R. H. Mortimer, Mohammed Zia Ul Haq Katshu, Lisa Chakrabarti
Summary: Psychosis and the use of second-generation antipsychotics (SGAs) are risk factors for developing metabolic syndrome (MetS). SGAs worsen metabolic abnormalities, leading to increased risks of severe weight gain, type 2 diabetes, and cardiovascular disease. Mitochondrial dysfunction is a hallmark of MetS, but the mechanisms through which SGAs induce MetS and how mitochondria are involved in this process are still unclear.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Pharmacology & Pharmacy
Bhanu Gupta, Kok-Seng Chee, Li-Qi Neo, Charmaine Tang, Jayaraman Hariram, Geoffrey Chern-Yee Tan, Swapna Verma, Sutapa Basu, Deva-Priya Appan, Chan-Chun Ting, Edimansyah Abdin, Jimmy Lee
Summary: The study found that adding low-dose aripiprazole did not significantly affect the overall weight of subjects, but led to significant weight loss and improvements in metabolic parameters for those on clozapine. Olanzapine group showed significant improvement in triglycerides, with trends in other metabolic parameters, while the risperidone group did not significantly improve in weight or metabolic parameters.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY
(2021)
Article
Psychiatry
Elena G. Kornetova, Alexander N. Kornetov, Irina A. Mednova, Anastasia A. Goncharova, Valeria Gerasimova, Ivan Pozhidaev, Anastasiia S. Boiko, Arkadiy Semke, Anton J. M. Loonen, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: The study reveals significant variations in the prevalence of metabolic syndrome among patients with schizophrenia in different psychiatric hospitals within the same region, highlighting the importance of individualized approaches to minimize the risk of its occurrence based on the specific characteristics of each hospital.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Neurosciences
Madhura P. Dixit, Shivkumar S. Sammeta, Mrunali D. Dhokne, Shubhada Mangrulkar, Manoj A. Upadhya, Milind J. Umekar, Brijesh G. Taksande, Nandkishor R. Kotagale
Summary: The study found that agmatine has a protective effect against olanzapine-induced obesity, reducing weight gain, feeding efficiency, adiposity index, and improving dysregulated lipid metabolism.
BRAIN RESEARCH BULLETIN
(2022)
Article
Biochemistry & Molecular Biology
Bato Korac, Andjelika Kalezic, Vanja Pekovic-Vaughan, Aleksandra Korac, Aleksandra Jankovic
Summary: Life is defined as an instantaneous encounter of circulating matter and flowing energy, and the relationship between redox biology and metabolism forms a dynamic balance in health, but disruption can lead to disease. The rising prevalence of metabolic diseases presents challenges in understanding, diagnosing, and treating them, emphasizing the need for research on novel redox-metabolic biomarkers.
Review
Biochemistry & Molecular Biology
Aiperi K. Khasanova, Vera S. Dobrodeeva, Natalia A. Shnayder, Marina M. Petrova, Elena A. Pronina, Elena N. Bochanova, Natalia Lareva, Natalia P. Garganeeva, Daria A. Smirnova, Regina F. Nasyrova
Summary: This study reviewed blood and urinary biomarkers associated with AIMetS, finding that there is currently no consensus on the role of any specific urinary biomarker. However, evaluating urinary biomarkers may be crucial for developing personalized prevention and treatment strategies.
Article
Cell Biology
Martine Uittenbogaard, Kuntal Sen, Matthew Whitehead, Christine A. Brantner, Yue Wang, Lee-Jun Wong, Andrea Gropman, Anne Chiaramello
Summary: This study aimed to establish the mitochondrial etiology of the proband's progressive neurodegenerative disease suggestive of an atypical Leigh syndrome. Through mitochondrial bioenergetic investigations and whole exome sequencing, three heterozygous nuclear variants associated with Leigh syndrome were identified, providing insights for the development of diagnostic and therapeutic strategies for atypical Leigh syndrome.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Psychiatry
Marc-Andre Nolin, Marie-France Demers, Chloe Rauzier, Roch-Hugo Bouchard, Camille Cadrin, Jean-Pierre Despres, Marc-Andre Roy, Natalie Almeras, Frederic Picard
Summary: The study found that IGFBP-2 levels were negatively correlated with waist circumference, insulin sensitivity, and plasma triglycerides in male schizophrenia patients treated with olanzapine or risperidone. Lower IGFBP-2 levels below 220 ng/mL were associated with a higher proportion of men with a hypertriglyceridemic waist phenotype compared to those with levels above this threshold.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
(2021)
Review
Endocrinology & Metabolism
Milica M. Borovcanin, Katarina Vesic, Milena Jovanovic, Natasa R. Mijailovic
Summary: Recent studies have suggested that patients with schizophrenia have specific immunometabolic profiles, with elevated levels of Gal-3 potentially linked to antipsychotic treatment and impacting the onset of inflammation, development of obesity, and cognitive changes. Animal studies have shown that downregulation of Gal-3 can be beneficial for insulin regulation of obesity and cognitive preservation. Strategies involving plasma exchange, particularly in the context of Gal-3 elimination, are discussed in this review.
WORLD JOURNAL OF DIABETES
(2021)
Review
Psychiatry
Marius H. Sneller, Nini de Boer, Sophie Everaars, Max Schuurmans, Sinan Guloksuz, Wiepke Cahn, Jurjen J. Luykx
Summary: Factors associated with metabolic syndrome (MetS) in patients with schizophrenia spectrum disorders using second-generation antipsychotics (SGA) include clinical factors such as age, gender, BMI, SGA exposure, and biochemical factors like hypo-adiponectinemia, elevated CRP levels, and high WBC count. Moreover, a genetic factor, the rs1414334 C-allele of the HTR2C-gene, was found to be associated with MetS in SGA users. Identifying these factors may help predict and prevent MetS in patients using SGAs.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Clinical Neurology
Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns
Summary: This study used a polygenic score (PGS) and electroencephalography (EEG) data analysis to identify potential predictors for treatment outcomes in major depressive disorder (MDD). The results suggest the existence of a stable EEG network related to antidepressant-response that has potential as a predictor for MDD treatment, particularly in the case of venlafaxine.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2024)